BiPER Therapeutics
Mehdi Chelbi is a seasoned biotechnology entrepreneur and executive, currently serving as Co-founder and Chief Executive Officer of BiPER Therapeutics, which focuses on developing innovative small molecule therapies for cancer treatment. Chelbi co-founded G.CLIPS biotech, emphasizing early drug and antibody discovery, and Landmark BioVentures AG, a hub for developing first-class therapeutics. In addition, Chelbi co-founded Duhn Therapeutics, dedicated to advancing immunological therapies for cancer patients. As Founder and CEO of Nadaya Life Sciences, Chelbi provides strategic development services to innovative life sciences companies. Previous experience includes significant roles at 4clinics and IDEALP-PHARMA, where Chelbi focused on business development and corporate strategy. Educational credentials include a Master’s degree in Biology from Université Claude Bernard Lyon 1 and an MSc in Biotechnology from the University of Lille 1 Sciences and Technology.
This person is not in any teams
This person is not in any offices
BiPER Therapeutics
BiPER Therapeutics is developing a first-in-class pipeline of therapeutics overstressing cells to cure patients. The company’s lead compound, BPR001, is a first-in-class small molecule therapeutic targeting BiP, an oncogenic protein shown to have a critical role in cancer